Acorda Therapeutics logo
Acorda Therapeutics ACOR
report update icon

Quarterly report 2024-Q1
added 05-16-2026

Acorda Therapeutics Deferred Revenue | ACOR

Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.
Features of the metric
  • Sources of future cash inflows
    A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability.
  • Assessment of operational stability
    Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages.
  • Risks and obligations
    Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results.
  • Analysis of liquidity and cash flow
    Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks.
  • Impact on company valuation
    In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).

Annual Deferred Revenue Acorda Therapeutics

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
227 K 384 K - - - - 9.06 M 9.06 M 9.06 M 9.06 M 9.06 M 38.3 M 9.06 M 9.43 M 9.43 M - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
38.3 M 227 K 10.2 M

Quarterly Deferred Revenue Acorda Therapeutics

2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1 2010-Q3 2010-Q2
294 K 465 K 548 K 384 K 384 K - - - - - - - - - - - - - - - - 9.06 M 9.06 M 9.06 M 9.06 M 9.06 M 9.06 M 9.06 M 9.06 M 9.06 M 9.06 M 9.06 M 9.06 M 9.06 M 9.06 M 9.06 M 9.06 M 9.06 M 9.06 M 9.06 M 9.06 M - - - - - - - 9.06 M 9.06 M 9.06 M 9.06 M 9.43 M 9.43 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
9.43 M 294 K 7.69 M

Deferred Revenue of other stocks in the Biotechnology industry

Issuer Deferred Revenue Price % 24h Market Cap Country
Galapagos NV Galapagos NV
GLPG
443 M - - $ 1.83 B belgiumBelgium
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
538 K $ 4.63 21.05 % $ 20 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
5.04 M $ 6.78 0.89 % $ 296 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
1.5 M - 368.57 % $ 41.9 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
56 K - - $ 35.3 M usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
53.2 M - 0.52 % $ 821 M danmarkDanmark
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
101 M - -0.04 % $ 2.62 B usaUSA
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
566 K - -23.04 % $ 26.6 M usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
687 K - - $ 69.7 B britainBritain
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
16.6 K - - $ 109 M usaUSA
ImmunoGen ImmunoGen
IMGN
13.9 M - - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
658 K - -8.77 % $ 12.4 M israelIsrael
Cidara Therapeutics Cidara Therapeutics
CDTX
9.8 M - - $ 1.41 B usaUSA
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
800 K - -2.99 % $ 2.47 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
1.72 M - -4.8 % $ 255 M usaUSA
bluebird bio bluebird bio
BLUE
1.5 M - - $ 546 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
2.35 M - - $ 35.4 M usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
31.8 M - - $ 728 M usaUSA
Regulus Therapeutics Regulus Therapeutics
RGLS
6 K - - $ 155 M usaUSA
NGM Biopharmaceuticals NGM Biopharmaceuticals
NGM
366 K - - $ 127 M usaUSA
Aravive Aravive
ARAV
4.41 M - -13.39 % $ 1.45 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
1.24 M $ 84.95 0.13 % $ 7.99 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
2.91 M - 2.71 % $ 14 M usaUSA
Gilead Sciences Gilead Sciences
GILD
202 M $ 166.01 -0.31 % $ 207 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
36.9 M $ 22.14 -1.6 % $ 248 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
2.65 M - - $ 2.02 B usaUSA
Orgenesis Orgenesis
ORGS
105 K - -33.86 % $ 61.2 M usaUSA